WT1 and myelodysplastic syndrome: LAAs such as New York esophageal squamous cell carcinoma-1 (NYESO-1) in multiple myeloma [4] or Wilms tumor antigen 1 (WT1)-TCR in AML and myelodysplastic syndrome (MDS) [5,6,7] have been clinically investigated and can be employed both in a autologous and in a allogeneic setting.